Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon wins FDA approval for lymphoma drug
According to the company, the data supporting the FDA approval show that Treanda is effective, has a tolerable side effect profile in patients with indolent non-Hodgkin’s lymphoma (NHL)
According to the company, the data supporting the FDA approval show that Treanda is effective, has a tolerable side effect profile in patients with indolent non-Hodgkin’s lymphoma (NHL)
Adenosine injection is indicated for supraventricular tachycardia in cardiac patients. Arthur Przybyl, Akorn’s president and CEO, said: “We are pleased to announce the abbreviated new drug application (ANDA)
New long-term histology results were presented from a cohort of 57 nucleoside-naive patients from rollover study ETV-901. ETV-901 provided long-term treatment with Baraclude 1mg for patients who have
In the six week, international, randomized, double-blind, placebo controlled study, 316 patients with an established diagnosis of schizoaffective disorder, who were experiencing acute symptoms, received either 6mg/day or
These new data show that patients who received Viread for up to 96 weeks experienced sustained suppression of hepatitis B virus (HBV) levels in the blood (91% and
ColonView testing can be used for simple and cost-effective identification of patients with fecal occult blood, which is a well-known marker for colorectal cancer and pre-cancerous large adenomas.
These studies have demonstrated that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, the company plans
In interim findings from the first 28 days of treatment for the first cohort of 50 treatment naive hepatitis C virus plus (HCV+), genotype 1, patients (once daily
According to the company, Isoplex will be used in situations where a patient is losing blood, such as trauma or surgery, and there is a need to increase
The company asked the European Medicines Agency (EMEA) to review its manufacturing and clinical development plan for RIGScan CR. The EMEA concurred that Neoprobe could use updated and